Cencora, Inc. (COR) Earnings Call Transcripts

Cencora, Inc.'s Latest Earnings Call - Q4 FY2026

In the fourth quarter of fiscal 2026, Cencora, Inc. reported consolidated revenue of $88.4 billion, a 6% increase year-over-year, and adjusted diluted EPS of $4.66, up 21%. The company maintained its long-term growth targets while introducing new segment reporting that emphasizes its focus on specialty pharmaceuticals. Management provided fiscal 2027 guidance, expecting adjusted diluted EPS in the range of $19.40 to $19.75, reflecting growth of 8% to 10%, and consolidated revenue growth of 3% to 5%.

Reported metrics

Guidance from management

For fiscal 2027, Cencora expects adjusted diluted EPS in the range of $19.40 to $19.75, reflecting growth of 8% to 10%. Consolidated revenue growth is anticipated to be in the range of 3% to 5%.

What management said

Thank you, Eva. Our fiscal 2027 guidance reflects our confidence in the strength of the business in our team, our strategy and our ability to deliver sustainable growth and long-term value for customers and shareholders. With that, we'll open the call for questions. Operator?

Sure. Lisa, the Specialty and Pharmaceutical Distribution and Provider Services segment, as you saw in our materials expected operating income growth of 18% to 21%. And that's above our long-term growth algorithm. And I would remind you, we have the wraparound of One Oncology for the first 4 months of the fiscal year. So outside of that impact, our underlying growth would have been in line with our algorithm of mid-t...

What analysts pressed on

Analysts expressed concerns regarding the impact of changes in reimbursement policies and the competitive landscape, particularly in specialty pharmaceuticals. There were inquiries about the organic growth rate of specialty and how upcoming biosimilar conversions might affect margins.

Main topics on the call

• Revenue Growth — Cencora achieved consolidated revenue of $337 billion for fiscal 2026, marking a 5% increase driven by growth in both U.S. and International Healthcare Solutions segments. Management stated, "Strength in specialty sales ...
• Adjusted EPS Growth — The company reported adjusted diluted EPS of $4.66 for Q4, representing a 21% increase year-over-year. This growth was attributed to strong operational performance and share repurchases, as noted by management: "This res...
• New Segment Reporting — Cencora introduced a new organizational structure with two reporting segments: Specialty Pharmaceutical and Provider Services, and Pharmaceutical Distribution and Services. This change aims to enhance operational executi...
• Fiscal 2027 Guidance — Management provided fiscal 2027 guidance, expecting adjusted diluted EPS between $19.40 and $19.75, reflecting growth of 8% to 10%. Additionally, they forecast consolidated revenue growth of 3% to 5%, indicating a cautio...

Read the full Cencora, Inc. transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 79 Cencora, Inc. earnings call transcripts on record, spanning January 9, 2020 to November 4, 2026. Based on this history, Cencora, Inc. reports quarterly. The most recent call on file is dated November 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

COR

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

79

First call

January 9, 2020

Most recent

November 4, 2026

Reporting cadence

quarterly